Press Releases
Press Releases
| 11/3/2011 |
TakstaTM (fusidic acid) Demonstrates Activity against MRSA Isolated from Cystic Fibrosis Patients - Cempra Pharmaceuticals will be presenting data demonstrating Taksta's activity against Methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from cystic fibrosis (CF) patients and demonstrating solithromycin's anti-inflammatory activity in a human lung epithelial.... |
| 10/20/2011 |
Additional Data on the Mechanistic Characterization of Adverse Events of Voriconazole and Telithromycin to be Presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) - Additional data will be presented on the mechanistic characterization of adverse events reported with the azole antifungal, voriconazole, and the ketolide antibiotic, telithromycin, at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA). The.... |
| 10/12/2011 |
Cempra Holdings, LLC Files Registration Statement for Proposed Initial Public Offering - Cempra Holdings, LLC, the parent holding company of Cempra Pharmaceuticals, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to its proposed initial public offering..... |
| 9/16/2011 |
Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) - Cempra Pharmaceuticals today announced abstracts to be presented on its fourth generation macrolide and novel fluoroketolide antibiotic, solithromycin (CEM-101), at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17 to 20, 2011.... |
| 9/15/2011 |
Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP) - Cempra Pharmaceuticals today announced results from its Phase II clinical trial investigating the efficacy, safety and tolerability of oral administration of our fourth generation macrolide, solithromycin (CEM-101), a fluoroketolide antibiotic, in comparison with oral.... |
| 5/31/2011 |
Cempra Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference - Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Jefferies 2011 Global Healthcare Conference at 1:30 p.m. EDT, June 6, 2011, at the Grand Hyatt in New York City. Dr. Fernandes will provide.... |
| 5/18/2011 |
Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris - Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at two upcoming investor conferences in Paris. Dr. Fernandes will present at 18th Annual Euro-Biotech Forum at 9:45 a.m. CET, May 24, at the... |
| 5/7/2011 |
Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial - Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced an oral presentation showing that intravenous (IV) solithromycin demonstrates excellent tolerability and a favorable pharmacokinetic (PK) profile at IV doses up to 800 mg. Oral administration... |
| 5/2/2011 |
Fusidic Acid (TAKSTA™, CEM-102) is Active, In Vitro, Against Methicillin-Resistant Staphylococcus Aureus (MRSA) Strains Isolated from Cystic Fibrosis Patients - Researchers from the Hershey Medical Center today announced the publication of research demonstrating that the antibiotic, fusidic acid, is active against MRSA strains isolated from cystic fibrosis (CF) patients. In addition, fusidic acid did not antagonize the activity of... |
| 5/2/2011 |
Cempra Pharmaceuticals to Present Data on Solithromycin (CEM-101) and TAKSTATM (CEM-102) at the 21st European Congress of Clinical Microbiology and Infectious Disease (ECCMID)/27th International Congress of Chemotherapy (ICC) - Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced its schedule of presentations at the 21st European Congress of Clinical Microbiology and Infectious Disease (ECCMID)/27th International Congress of Chemotherapy (ICC) in Milan, Italy, May 7-10, 2011... |
| 4/28/2011 |
Fusidic Acid (TAKSTATM, CEM-102) is Active, In Vitro, Against Methicillin-Resistant Staphylococcus Aureus (MRSA) Strains Isolated from Cystic Fibrosis Patients - Researchers from the Hershey Medical Center today announced the publication of research demonstrating that the antibiotic, fusidic acid, is active against MRSA strains isolated from cystic fibrosis (CF) patients. In addition, fusidic acid did not antagonize the activity of two... |
| 4/7/2011 |
Cempra Pharmaceuticals To Present At Two Upcoming Cambridge Healthtech Institute (CHI) Conferences - Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at two upcoming CHI conferences. Dr. Fernandes will present at the Second Annual Anti-Inflammatories: Small Molecule Approaches Conference at 5 p.m. PDT, April 12, at the Hilton San Diego Resort in San Diego. Her presentation is entitled... |
| 3/30/2011 |
Cempra Pharmaceuticals To Present At Two Upcoming Investor Conferences - Cempra Pharmaceuticals Inc. today announced presentations at two upcoming investor conferences. Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at the Needham & Company 10th Annual Healthcare Conference at 10 a.m. EDT, April 6, at The New York Palace... |
| 3/3/2011 |
Cempra Expands Clinical Management Team To Advance Leading Antibacterial Clinical Programs Solithromycin and Takstatm - Cempra Pharmaceuticals today announced the appointment of David Oldach, M.D. as vice president, clinical research as well as announcing an expansion of its clinical development team to manage the company's leading clinical programs, solithromycin and TAKSTA through advanced clinical... |
| 3/2/2011 |
Cempra Pharmaceuticals To Present at the Cowen And Company 31st Annual Health Care Conference - Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for... |
| 1/12/2011 |
Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (Cem-101) at the 5th Annual Phemce Stakeholders Workshop and Barda Industry Day - Cempra Pharmaceuticals presented the broad spectrum and potent activity profile of solithromycin (CEM-101), the first fluoroketolide antibiotic, at the 5th Annual PHEMCE stakeholders workshop and Biomedical Advanced Research and Development Authority (BARDA) industry day on January 10 to 12... |
| 1/5/2011 |
Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development - Cempra Pharmaceuticals announced that Carl Foster has been named Executive Vice President of Business Development. Mr. Foster will be focusing on business development activities related to the company's two lead antibiotic programs, the next-generation fluoroketolide solithromycin (CEM-101)... |
| 12/1/2010 |
Molecular Mechanisms That Could Explain Unique Adverse Events Observed in Patients Treated With the Antibiotic Telithromycin (Ketektm) is Reported in Antimicrobial Agents and Chemotherapy - Cempra Pharmaceuticals and HiQScreen today announced the publication of research revealing the molecular mechanisms that could explain certain unique adverse events associated with the ketolide, telithromycin (KetekTM), which led to its restricted use. The study also showed... |
| 11/15/2010 |
Cempra Pharmaceuticals To Present At The Lazard 7th Annual Healthcare Conference Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Lazard 7th Annual Healthcare Conference at 9:00 a.m. EST, November 17, 2010, at the St. Regis New York in New York City. Dr. Fernandes will... |
| 11/3/2010 |
Cempra Pharmaceuticals' Solithromycin (Cem-101) Demonstrates Potent In Vitro And In Vivo Activity Against Malaria Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3 to 7 in Atlanta. The abstracts will present new information on solithromycin's... |
| 10/15/2010 |
Cempra Pharmaceuticals Presents New Data on its Multi-Drug Resistant Anti-Infective Portfolio, Solithromycin (Cem-101) and Takstatm (Cem-102), at the 48th Annual Meeting of the Infectious Diseases Society of America Cempra Pharmaceuticals today announced poster presentations on its novel fluoroketolide antibiotic, solithromycin (CEM-101), and the Company's proprietary front-loading oral dosing regimen of sodium fusidate, TAKSTA (CEM-102) at the 48th Annual Meeting... |
| 10/12/2010 |
Cempra Pharmaceuticals Names Richard Kent, M.D., to its Board of Directors Cempra Pharmaceuticals announced that Richard Kent, M.D., a partner at Intersouth Partners, has been appointed to Cempra's board of directors. Dr. Kent will replace Garheng Kong, M.D., Ph.D., M.B.A., as Intersouth's representative on the board. Dr. Kong, who has... |
| 9/14/2010 |
Cempra Pharmaceuticals to Present at the Stifel Nicolaus Healthcare Conference 2010 Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Stifel Nicolaus Healthcare Conference 2010 at 10:20 a.m. EDT, September 16, 2010, at the Four Seasons Hotel in Boston. Dr. Fernandes... |
| 9/9/2010 |
Cempra Pharmaceuticals Presents New Data On TakstaTM (Cem-102, Sodium Fusidate) At The 50th Interscience Conference On Antimicrobial Agents And Chemotherapy (Icaac) Cempra Pharmaceuticals today announced abstracts to be presented on its oral anti-MRSA antibiotic, TAKSTA (sodium fusidate, formerly CEM-102), at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 12 to 15, 2010, in Boston... |
| 9/9/2010 |
Cempra Pharmaceuticals Presents New Data On Its Next Generation Fluoroketolide, Solithromycin (Cem-101) At The 50th Interscience Conference On Antimicrobial Agents And Chemotherapy (Icaac) Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 12 to 15, 2010, in Boston... |
| 9/8/2010 |
Cempra Pharmaceuticals Will Present New Data On Solithromycin (Cem-101) And Takstatm (Cem-102) At The 50th Interscience Conference On Antimicrobial Agents And Chemotherapy (Icaac) Cempra Pharmaceuticals today announced its schedule of 16 poster presentations at the 50TH Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, Mass., on September 12-15, 2010... |
| 9/8/2010 |
Cempra Pharmaceuticals Initiates Both a Phase 2 Study With an Oral Formulation and a Phase 1 Study of the Intravenous Formulation of Solithromycin (CEM-101), a Novel Fluoroketolide Cempra Pharmaceuticals announced that it is moving forward in its dual approach to the development of solithromycin (CEM-101), a fluoroketolide which is first of a new generation of macrolide-ketolide antibiotics for treatment of community-acquired... |
| 5/18/2010 |
Cempra Pharmaceutical's Cem-101 Demonstrates Potent Anti-Inflammatory Activity, Compared To Other Macrolide Antibiotics, In An Inflammation Cell Model At The American Thoracic Society 2010 International Conference Cempra Pharmaceuticals today announced the results from two poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, at the American Thoracic Society 2010 International Conference, May 14 to 19, 2010, in New Orleans... |
| 5/6/2010 |
Cempra Pharmaceuticals Names Mark W. Hahn as Executive Vice President and Chief Financial Officer Cempra Pharmaceuticals Inc. today announced the appointment of Mark W. Hahn as executive vice president and chief financial officer... |
| 5/4/2010 |
Cempra Announces Positive Results From Its Phase 2 Clinical Trial Of Takstatm (Sodium Fusidate) In Patients With Acute Bacterial Skin And Skin Structure Infections (Absssi) Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA™ (CEM-102, sodium fusidate), the company’s oral, anti-methicillinresistant Staphylococcus aureus (MRSA) antibiotic. The study demonstrated efficacy... |
| 4/10/2010 |
Cempra pharmaceuticals presents new data on its multi-drug resistant anti-infective portfolio, cem-101 and takstatm (cem-102), at the 20th european congress of clinical microbiology and infectious disease Cempra Pharmaceuticals today announced poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102 (TAKSTA), the company's proprietary front-loading oral dosing regimen of sodium fusidate, at the 20th European Congress of Clinical Microbiology... |
| 4/8/2010 |
Cempra pharmaceuticals will present new data on cem-101 and takstatm (cem-102) at the 20th european congress of clinical microbiology and infectious disease Cempra Pharmaceuticals today announced its schedule of poster presentations at the 20th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna, Austria, on April 10-13, 2010.... |
| 4/6/2010 |
Cempra announces expansion of clinical management team to advance leading antibacterial clinical programs takstatm and cem-101 Cempra Pharmaceuticals today announced the expansion of its clinical development team to manage the company's leading clinical programs, CEM-101 and TAKSTA (formerly CEM-102) through advanced clinical development. The four appointments, including Susan R. Moriarty, M.D. and Jennifer .... |
| 3/10/2010 |
Cempra announces The Completion of Phase 1 Studies for cem-101, a next-generation macrolide Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study.... |
| 3/4/2010 |
Cempra Pharmaceuticals To Present At The Cowen And Company 30th Annual Health Care Conference Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Cowen and Company 30th Annual Health Care Conference at 3 p.m. EST, March 8, 2010, at The Boston Marriott Copley Place in Boston... |
| 1/19/2010 |
Cempra Completes Enrollment Of Phase 2 Portion Of Phase 2/3 Clinical Trial Of Takstatm (Cem-102 Or Sodium Fusidate) For Treatment Of Acute Bacterial Skin And Structure Infections Cempra Pharmaceuticals today announced completion of enrollment of the Phase 2 portion of its Phase 2/3 clinical trial of TAKSTA... |
| 1/8/2010 |
Cempra Pharmaceuticals Names Donald C. Olsen Executive Vice President Of Business Development Cempra Pharmaceuticals Inc. today announced the appointment of Donald C. Olsen as executive vice president of business development. Mr. Olsen will oversee the... |
| 11/25/2009 |
Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Piper Jaffray 21st Annual Health Care Conference... |
| 11/13/2009 |
Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will... |
| 10/29/2009 |
Data Presented on Cempra Pharmaceutical's CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates Cempra Pharmaceuticals today announced a presentation on its novel fluoroketolide antibiotic, CEM-101, at the Infectious Diseases Society of America... |
| 10/29/2009 |
Presentations of Cempra Pharmaceutical's CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate Cempra Pharmaceuticals today announced data presentations of its lead antibiotic candidate, CEM-102 (fusidic acid)... |
| 10/22/2009 |
Cempra Pharmaceuticals Will Present New Data on CEM-101 and CEM-102 at the Infectious Disease Society Of America, 47th Annual Meeting Cempra Pharmaceuticals today announced its schedule of oral and poster presentations at the Infectious Disease Society of America... |
| 09/09/2009 |
Cempra Pharmaceuticals Initiates Phase 2/3 Clinical Study for an Oral Antibiotic to Treat Acute Bacterial Skin Structure Infections Cempra Pharmaceuticals today announced that enrollment is underway in an adaptive design Phase 2/3 clinical study with CEM-102 for patients suffering... |
| 08/12/2009 |
Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors Cempra Pharmaceuticals today announced the appointment of John H. Johnson, Chief Executive Officer of ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to the company’s Board of Directors... |
| 05/14/2009 |
Cempra Pharmaceuticals Closes $46M Series C Financing Funds will advance clinical development of two lead antibiotic compounds and the company's pre-clinical pipeline... |
| 04/28/2009 |
Cempra Pharmaceuticals Inc. announces lead macrolide is active in vitro against clinically significant antibiotic-resistant pathogenic organisms Cempra Pharmaceuticals today announced the publication of new research in the May issue of Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology, demonstrating that its lead compound, CEM-101 ... |
| 09/30/2008 |
Cempra Pharmaceuticals and Biovista Enter Agreement For Macrolide Clinical Trial Design Support Studies Cempra Pharmaceuticals, Inc., and Biovista, Inc., announced today that they have entered into a research agreement to systematically identify and profile adverse event associations for members of the macrolide drug class ... |
| 10/03/2006 |
Aisling Capital Joins I. Wistar Morris III and Intersouth Partners as a Lead Investor in Cempra Pharmaceuticals Anti-infective biotechnology company Cempra Pharmaceuticals announced today that it has added Aisling Capital as an investor ... |
| 08/16/2006 |
Cempra Pharmaceuticals Raises $14 Million Round of Financing Cempra Pharmaceuticals, a biotechnology company developing anti-infective medicines ... |
| 04/04/2006 |
Cempra Pharmaceuticals Receives Exclusive Rights from Optimer Pharmaceuticals for Its Macrolide Antibacterial Program Cempra Pharmaceuticals, Inc. announced that Optimer Pharmaceuticals has granted to Cempra exclusive worldwide rights (except ASEAN countries ... |